Levodopa inhalation - Acorda Therapeutics

Drug Profile

Levodopa inhalation - Acorda Therapeutics

Alternative Names: CVT-301; INBRIJA™; Inhaled L-dopa - Civitas Therapeutics

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Parkinson's disease
  • Phase I Asthma; Smoking withdrawal

Most Recent Events

  • 29 Jun 2017 Preregistration for Parkinson's disease (Adjunctive treatment) in USA (Inhalation)
  • 29 Jun 2017 Acorda Therapeutics announces its intention to submit a MAA in Europe for Parkinson's disease, by the end of 2017
  • 05 Jun 2017 Interim adverse events data from a phase III trial in Parkinson's disease released by Acorda Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top